Alpha Tau Medical Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
DRTS Nasdaq 2834 www.alphatau.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alpha Tau Medical Ltd.

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 - Mar 31st, 2026 7:15 am
Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased - Mar 19th, 2026 9:47 am
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference - Mar 16th, 2026 8:02 am
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update - Mar 9th, 2026 2:02 pm
Alpha Tau price target raised to $12 from $9 at H.C. Wainwright - Feb 25th, 2026 8:30 am
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT - Feb 24th, 2026 6:51 pm
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer - Feb 24th, 2026 7:00 am
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead - Jan 29th, 2026 7:00 am
New Strong Sell Stocks for January 27th - Jan 27th, 2026 2:02 am
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event - Jan 23rd, 2026 12:50 pm
New Strong Sell Stocks for January 20th - Jan 20th, 2026 7:12 am
Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer - Jan 20th, 2026 7:00 am
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study - Jan 6th, 2026 7:00 am
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) - Jan 5th, 2026 7:00 am
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference - Dec 18th, 2025 7:00 am
Sidoti Events, LLC's Year-End Virtual Investor Conference - Dec 9th, 2025 10:48 am
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University - Dec 9th, 2025 7:00 am
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium - Dec 4th, 2025 7:00 am
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer - Dec 2nd, 2025 7:00 am
Alpha Tau to Participate in December Investor Conferences - Dec 1st, 2025 7:00 am